Pivotal phase III trial results of Taltz (ixekizumab) in plaque psoriasis published in New England Journal of Medicine- Eli Lilly

Eli Lilly announced that the New England Journal of Medicine has published detailed results from three pivotal Phase III studies�UNCOVER-1, UNCOVER-2 and UNCOVER-3�that demonstrated the efficacy and safety of Taltz (ixekizumab) through 60 weeks in patients with moderate-to-severe plaque psoriasis. This publication also detailed 12-week efficacy data for patients treated with Taltz in UNCOVER-1. In all three studies, responders to Taltz through 12 weeks demonstrated high levels of skin clearance through 60 weeks.

In UNCOVER-1, Taltz given every two weeks was statistically superior to placebo, with high levels of clearance achieved at 12 weeks among patients treated with Taltz, the majority of whom achieved virtually clear (PASI 90) or completely clear skin (PASI 100, sPGA 0). In UNCOVER-1 and UNCOVER-2, high levels of clearance also were achieved through 60 weeks among patients treated with Taltz every two weeks who achieved clinically meaningful response (sPGA 0 or 1) at 12 weeks, the majority of whom achieved virtually clear or completely clear skin through 60 weeks when treated with Taltz every four weeks. In UNCOVER-3, high levels of clearance were also achieved with Taltz given every four weeks through 60 weeks among patients initially treated with Taltz every two weeks.

See: "Phase III Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis" Kenneth B. Gordon et al. New England Journal of Medicine June 8, 2016 online DOI: 10.1056/NEJMoa1512711